pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

neurorx PRESS RELEASE ARCHIVE

May 25, 2021

NRx Pharmaceuticals, Inc. Commences Trading on Nasdaq as NRXP, Following Merger Between NeuroRx, Inc. and Big Rock Partners Acquisition Corp (Nasdaq:BRPA)

Apr 28, 2021

NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

Apr 19, 2021

NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

Apr 6, 2021

NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

Mar 29, 2021

NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

Mar 26, 2021

NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure

Mar 9, 2021

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Mar 9, 2021

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Feb 23, 2021

NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint

Feb 9, 2021

NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19

Feb 3, 2021

NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health

Jan 11, 2021

NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial

Dec 30, 2020

NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

Dec 7, 2020

NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

Nov 24, 2020

NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

Nov 13, 2020

NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure

Nov 5, 2020

NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020

Nov 4, 2020

NeuroRx Receives Notice of Allowance from USPTO for a Formulation for the Treatment of Post-Traumatic Stress Disorder

Oct 13, 2020

NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19

Sep 30, 2020

NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)

Sep 23, 2020

NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy

Sep 21, 2020

Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners

Jul 29, 2020

FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19: Currently in development by NeuroRx and Relief Therapeutics under Fast Track Designation

Jul 16, 2020

NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19

Jun 11, 2020

Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients With Respiratory Failure to Houston Methodist Hospital

Jun 2, 2020

Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

Mar 26, 2020

RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress USA - English Israel - English

Feb 10, 2020

NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference

Jan 8, 2020

NeuroRx Drug for Suicidal Bipolar Depression Receives Notification of Patent Allowance

Oct 23, 2019

NeuroRx Secures HK$ 750 Million Capital Commitment From The Gem Group for Development of NRX-101

Sep 9, 2019

NeuroRX to Present at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019

Jul 9, 2019

NeuroRx Initiates Pivotal Study for NRX-101, a Breakthrough Designation Therapy Targeting Suicidal Bipolar Depression

Jun 3, 2019

NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention

May 30, 2019

NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Dec 20, 2018

NeuroRx Research Developed Novel Brain MRI Measures of Chronic Lesion Activity and Progressive Pathology in People With Multiple Sclerosis

Dec 13, 2018

NeuroRx Presents Phase 2 Efficacy and Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Nov 13, 2018

NeuroRx Receives FDA Breakthrough Therapy Designation for NRX-101, First Oral Drug Targeting Suicidal Bipolar Depression

Jun 11, 2018

NeuroRx, Inc. Completes Phase 2b/3 Feasibility Enrollment for First Glx-Targeted Oral Drug Targeting Suicidal Bipolar Depression

Jan 3, 2018

NeuroRx Retains J.P. Morgan as Financial Advisor

Dec 27, 2017

NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior (ASIB)

Sep 6, 2017

NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression

Apr 12, 2017

NeuroRx Partners with Leading Patient Advocacy Groups and Experts in the Bipolar Disorder Community to Launch 1st Global “Voice of the Patient” Survey to Gain Insights Into Care Received During Hospitalization for a Suicidal Crisis

Jan 4, 2017

NeuroRx announces FDA IND clearance for NRX-101 phase 2b/3 study and publication of promising biomarker data

Oct 18, 2016

NeuroRx solidifies Intellectual Property Position - receives notice of Allowance by US Patent Office

Sep 7, 2016

NeuroRx Announces Participation At The 18th Annual Rodman and Renshaw Global Investment Conference In New York City September 11-13, 2016

Jun 1, 2016

NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition

May 27, 2016

NeuroRx Wins Startup Competition at IATI-Biomed 2016, Israel’s Leading Life Science Conference

Oct 21, 2015

American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression

Jun 24, 2015

NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression and Suicidality

Google Analytics Alternative